# FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D’Amico,Cristina Granetto,Marina Elena Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone |
| Citations | 1,101 |
| DOI | 10.1016/s1470-2045(15)00122-9 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://hdl.handle.net/11568/1093304 |
| OpenAlex ID | https://openalex.org/W2129998117 |
| PMID | 26338525 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Sara Lonardi](https://scholariq.org/researchers/sara-lonardi/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Paper topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.